Hosted on MSN5d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
The Straits Times24d
Always hungry, no matter how much they eat
They have Prader-Willi syndrome (PWS) – a rare neurodevelopmental and genetic condition where the “switch” in the brain that signals fullness never gets flipped on. PWS occurs when part of ...